19 results about "Transplant cell" patented technology

The present disclosure relates to a transplantable cell therapy product composition for diabetes mellitus that contains an aggregate of insulin-secreting cells derived from stem cells. In the present disclosure, an NF microwell array membrane was fabricated by applying a molding process to an electrospun, permeable, biodegradable polycaprolactone (PCL) NF membrane and thus allows gases and soluble factors to permeate therethrough. The NF microwell of the present disclosure could provide more nutrients to the iPSC aggregates than conventional impermeable PDMS microwells, thus enhancing survival and differentiation capabilities of the cells. Additionally, the NF membrane was attached singly to the subcutaneous tissue and to the surface of organs such as liver and peritoneum without the need for a fixing material or separate sutures and was integrated with surrounding tissues, resulting in higher insulin secretion than PDMS microwells. Therefore, the present disclosure can be effectively utilized as a composition for the prevention or treatment of diabetes.

The present disclosure relates to methods of treating, preventing, or modulating diabetes in a patient in need thereof using a device for transplanting cells into a host body, specifically a method of treating diabetes in a patient in need thereof, comprising: implanting a device in the patient, wherein the device comprises: a porous scaffold comprising an immunologically compatible polymer mesh forming the walls of at least one chamber, an opening at either or both of a proximal end and a distal end of the chamber, at least one removable, non-porous plug configured to be positioned within the lumen of the at least one chamber, maintaining the device in the patient's body until the device is infiltrated with vascular and connective tissues; and infusing the chamber with cells, wherein at least some of the cells express insulin

The invention relates to the technical field of nerve injury repair, in particular to a spinal cord injury repair system based on ordered collagen scaffold carried cell transplantation combined with electroacupuncture stimulation application. The invention provides a spinal cord injury repairing system, which comprises a biological material support transplanting module, a cell inoculating module and a spinal cord injury repairing module, and the electro-acupuncture stimulation module is used for applying electro-acupuncture stimulation to acupuncture points after the biological material stent inoculated with the cells is transplanted to the spinal cord injury part. According to the system, electroacupuncture stimulation and biomaterial stent transplantation cells are combined for application, the microenvironment can be remarkably improved, survival, differentiation and function integration of the transplantation cells can be promoted, meanwhile, muscle atrophy and joint degeneration are relieved, an innovative treatment system is provided for spinal cord injury, and the system has high clinical feasibility and is worthy of popularization and application. Good application prospects are realized in the field of spinal cord injury repair.

Novel methods are disclosed for treating patients with Parkinson's disease and other primary and secondary parkinsonian disorders by improving cell engraftment. Treating patients with antihyperlipidemic drugs and / or CSF-1R antagonists before, during, and / or after transplantation of DA neurons improves cell viability, engraftment, proliferation, migration, or differentiation of the administered DA neurons. Methods are disclosed for pre-treating patients to improve engraftment of administered cells. Methods are disclosed for pre-treating patients to improve engraftment of administered progenitor cells.

Nanoparticles, methods, and kits are provided for supplying nutrients and other therapeutic agents to transplanted cells. Nutrient deprivation is a significant factor which contributes to poor outcome of many cell transplants because cells receive insufficient nutrients until they are able to establish a functional microcirculation to support their metabolic and physiological needs after transplantation. Nanoparticles are provided for use in supplying nutrients and other therapeutic agents to transplanted cells to improve cell survival. Such nanoparticles can be used to supply nutrients and other factors to transplanted cells until the transplanted cells are able to develop a new microcirculation.

The present disclosure relates to cells for intravascular transplantation having hemocompatibility in which the blood coagulation mechanism and thrombosis reaction are inhibited by artificially modifying the F3 gene encoding CD142 that is an initiator of blood coagulation, using gene scissors technology to reduce or suppress the expression or activity of CD142, a method of producing the same, and a use thereof for preventing or treating liver disease and diabetes.

The invention relates to a myocardial progenitor cell and drug double-loaded hydrogel biological material and application thereof, and particularly provides a biological material compound which comprises an organic compound, living cells and a loading material, and the organic compound can induce expression of protease. The compound is used in the treatment process of myocardial infarction (MI), the functionality of transplanted cells is improved, and effective repair and functional recovery of damaged myocardium are promoted.

This invention provides compositions and methods for reducing the immunogenicity of cells for transplantation, including cell-based immunotherapy. [Solution] A vector encoding β2-microglobulin (B2M) modified RNA, along with a targeting moiety and other signaling and / or suicide genes, enables the efficient generation of engineered CAR T regulatory cells or other therapeutic cells derived from any source. The present invention provides, for example, vectors encoding β2-microglobulin (B2M) modified RNA and chimeric antigen receptors (CARs).

Provided herein are methods and systems of transplant cells and growing an ectopic tissue in a lymph node of a subject. In certain embodiments, the methods and systems provided herein enable minimally invasive cell transplantation to treat patients in need thereof. In certain embodiments, the methods and systems provided herein include the use of ultrasound endoscopy.

Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue. The mechanisms by which engraftment and integration of donor cells into the organ or tissue involve multiple membrane-associated and secreted forms of MMPs.

Antibodies which bind selectively to cardiac conduction system (CCS) cells, imaging and / or diagnostic reagents and compositions visualizing the CCS cells and therapeutic products and compositions comprising one or more of the antibodies. Methods for delivering therapeutic agents to the CCS cells. The disclosure further provides methods for visualizing the CCS cells in vivo in real time, including in a subject undergoing a cardiothoracic surgery or other cardiac intervention. Compositions and methods for isolation, purification, analyses and / or transplantation of the CCS cells, including pluripotent stem cell (hiPSC)-derived or human embryonic stem cell (hESC)-derived CCS cells.

To provide a method for producing T cells for transplantation, by which T cells having an improved duration in vivo can be produced, to provide T cells having an improved duration in vivo, and to provide a pharmaceutical composition containing the T cells.SOLUTION: A method for producing a T cell for transplantation, comprising a step (A) of increasing an expression level of a nitric oxide synthase interacting protein in a T cell. There is also provided a T cell into which a nucleic acid having a function of improving an expression level of a nitric oxide synthase interacting protein is introduced.SELECTED DRAWING: None

The invention relates to a long-acting hydrogen release system for assisting cell transplantation as well as a preparation method and application thereof, belongs to the technical field of medical treatment, and provides a long-acting hydrogen release system for assisting cell transplantation in order to provide a substance capable of performing targeted delivery to a cell transplantation part and continuously releasing high-dose H2. The long-acting hydrogen release system comprises a hydrogen release material with a particle size of 5 nm to 10 [mu] m and a hydrogel matrix, and the cells are dispersed in the system; the concentration of the hydrogen release material is 0.01 to 100 [mu] g / mL, and the content of the cells is 10000 to 100000000 cells / mL. The long-acting hydrogen release system is used for maintaining the activity and directional differentiation of transplanted cells in an in-vitro differentiation / balling process and maintaining the activity and characteristics of the transplanted cells in a pathological microenvironment after transplantation. In a malignant pathological microenvironment, hydrogen is continuously supplied, so that the activity of stem cell spheres assembled / differentiated into cartilage cell microspheres and the hyaline cartilage phenotype are effectively maintained, and the activity of transplanted stem cells and the hyaline cartilage differentiation potential are maintained by continuously supplying hydrogen; and continuously supplying hydrogen to maintain the activity and transparency of the transplanted cartilage cells.

The present application relates to the field of biotechnology, in particular to a preparation method of sound-sensitive stem cell-derived beta functional cells and application thereof. The preparation method provided by the present application introduces a prokaryote-derived engineered mechanosensitive ion channel MscL-G22S into human pluripotent stem cells, and combines with a directional differentiation technology to obtain pancreatic islet beta-like cells with ultrasonic response function. The cell product not only has a natural glucose-dependent insulin secretion capacity, but also has an additional function of being activated by low-intensity focused ultrasound in a non-invasive manner through the introduction of an exogenous ion channel. This double regulation mechanism significantly improves the functional maturity and response sensitivity of the transplanted cells in vivo, and can achieve a better blood glucose control effect under the same number of cells, thereby providing a technical possibility for reducing the amount of transplanted cells, reducing the volume of transplanted cells and expanding the transplanted site, and being suitable for popularization and application.

Polycaprolactone (PCL) scaffolds having macropores interconnected with micorpores are provided. Tissue grafts that include the PCL scaffold having therapeutic cells encapsulated within the macropores are also provided. Also provided are methods of making the PCL scaffold and the tissue graft, and methods of transplanting cells into an individual using the tissue graft.

Disclosed are therapeutic agents capable of trapping large proteins (e.g., CD45, CD148, and CD43) between the cell interface between transplanted cells and CD45-positive host effector cells (e.g., T cells, NK cells, B cells, or dendritic cells), as well as methods of their use and products made from such therapeutic agents. The therapeutic agents prevent or inhibit the formation of functional immune synapses, including physiological SMAC. They also result in sustained dephosphorylation of the signal transduction pathways.

The present invention relates to remodeling the hematopoietic niche to reconstitute immunity. In particular, the present invention discloses compositions and related methods for remodeling the bone marrow stroma using a scaffold material (e.g., a porous alginate hydrogel scaffold) containing one or more cell differentiation factors and one or more growth factors. These methods and compositions promote the formation of ectopic nodules or sites that can improve engraftment of transplanted cells and selectively drive the development of lymphocytes and reconstitution of adaptive immunity following hematopoietic stem cell transplantation.

Macroencapsulation devices for transplanting cells or tissues are provided. In addition, macroencapsulation devices for local delivery of a drug to establish local immunosuppressive therapy are provided.

The present invention relates to a composition for inhibiting the immunogenicity of mammalian cells and a method for producing low-immunogenic mammalian cells using the same. The present invention can be useful as an efficient cell therapy agent for allogeneic transplantation of stem cells or immune cells for the treatment of diseases, which maintains long-term activity while minimizing immune rejection in the recipient's body.